

## Medicines Patent Pool Governance Board Meeting #40

11-13 November 2025  
Virtual meeting

### Attendees

#### **Governance Board Members:**

Marie-Paule Kieny (Chair), Mojisola Christianah Adeyeye, Grégory Bonnaud<sup>1</sup>, Maureen Luba, Peter Maybarduk, Govindarajan Narayanan, Ntobeko Ntusi, Mathieu Saint-Arnaud, Maximiliano Santa Cruz<sup>2</sup>, Pushpagiri Vijayaraghavan<sup>3</sup>.

#### **Excused Board Members:**

N/A

#### **Non-voting Members:**

Robert Matiru and Jackson Hungu – Unitaids Representatives, Marion (Amy) Dietterich – World Intellectual Property Organization Representative, Tanuja Garde – World Trade Organization Representative; Yukiko Nakatani and Jicui Dong – World Health Organization Representatives; Peter Beyer – Expert Advisory Group Chair.

#### **Excused Non-voting Members:**

N/A

#### **Medicines Patent Pool Foundation Management Team:**

Charles Gore – Executive Director

Esteban Burrone – Policy, Strategy and Market Access Director, Jane Caldwell – Chief Operating Officer, Ruth Foley – Senior Manager, Monitoring and Evaluation<sup>4</sup>, Martin Friede – MPP mRNA Technology Transfer Consultant<sup>5</sup>, Gelise McCullough – Communications Director, Judith Federhofer – Business Development Director, Chan Park – General Counsel, Gosha Stehle – HR Manager<sup>6</sup>, Deborah Woodford – Finance Manager<sup>7</sup>, Agnese Tonnina – Senior Manager, Grants and Governance and Secretary of the MPP Governance Board.

---

<sup>1</sup> Did not attend the meeting on November 11<sup>th</sup>

<sup>2</sup> On November 12<sup>th</sup>, left the meeting at 16:00

<sup>3</sup> On November 13<sup>th</sup>, joined the meeting at 15:25

<sup>4</sup> Attended the Report from the SPC session on November 12<sup>th</sup>

<sup>5</sup> Attended mRNA Programme update session on November 11<sup>th</sup>

<sup>6</sup> Attended on November 13<sup>th</sup> only

## Summary of Decisions

### The Governance Board of the Medicines Patent Pool:

1. Approved the MPP 2026–2030 Strategy, pending incorporation of comments made by the Board during the meeting and final proofreading.
2. Agreed that the formal launch of the MPP 2026–2030 Strategy shall take place during the World Health Assembly (WHA) in May 2026 as an in-person event, potentially hosted at the French Permanent Mission in Geneva, subject to confirmation from the French authorities.
3. Requested the Management to develop a sequenced plan of preparatory activities, including the January webinar and targeted stakeholder webinars, to create momentum and ensure that the Strategy is well socialised ahead of the formal WHA launch.
4. Approved pausing the launch activities for RegPaL. The team will instead focus on assessing RegPaL Lite, which aims to reduce the resources required to populate and maintain the database, and will return with a proposal in May 2026 on whether a public launch is feasible given the resources available.
5. Expressed support for the Management's initiative to have a roundtable with the originator (innovator) industry and requested the Management to proceed with the proposed next steps and to present, during the May 2026 Board meeting, a summary of insights from the inaugural roundtable and a proposal on whether to continue with periodic roundtables or explore a more formalised engagement mechanism.
6. Approved the proposed amendments to the Private Investments and Whistleblower Policies.
7. Approved the 2026 budget, totalling CHF 12 million.
8. Approved the proposed additional amendments to the Travel and Expenses Policy, stressing the importance for Board Members and staff to make travel plans well in advance when exceptionally travelling in business class, in order to minimise costs to MPP.
9. Approved the amendments to the HR Policy.
10. Requested the Search Committee and Ganci Partners to begin the ED recruitment process in mid-January 2026, with the aim of making a decision at the May Board meeting when the Board will meet the finalists in person.
11. Agreed with the recommended changes for the following high risks: Strategic Risk 15: *Patents on key products are not licensed to MPP*, Strategic Risk 20: *MPP achieves a geographic scope below expectations of relevant stakeholders*, Strategic Risk 23: *Uptake*

*of prioritised/licensed products falls below 50% of projections due to limited funding, and Operational Risk 13: Major failures within the IT system. The Board further agreed to remove Strategic Risk 42: Lack of user engagement with LAPaL and to add the following two risks: Operational Risk 55: Insufficient funding to support the MedSuRe project implementation and Strategic Risk 56: Failure to successfully recruit a suitable Executive Director.*

12. Invited Board Members Mojisola Christianah Adeyeye and Peter Maybarduk to serve third terms, running respectively from 1 December 2025 to 30 November 2028, and from 1 April 2026 to 31 March 2029.
13. Agreed to assign Mathieu Saint-Arnaud to serve on both the Finance and Management Committee and the Ethics and Compliance Committee.